ReviewCurrent rheumatology reports2012
The management of stroke in antiphospholipid syndrome.
Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.The Cochrane database of systematic reviews · 2020Pooled it
- Stroke in Coronavirus Disease 2019: A Systematic Review.Journal of stroke · 2020Pooled it
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.The Cochrane database of systematic reviews · 2017Pooled it
- Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances.Rheumatology international · 2025Review
- Rheumatic diseases presenting with young ischemic stroke: Revelations from tertiary center experience.Northern clinics of Istanbul · 2025Article
- Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.Medicines (Basel, Switzerland) · 2024Review
- Neurovascular Issues in Antiphospholipid Syndrome: Arterial Vasculopathy from Small to Large Vessels in a Neuroradiological Perspective.Journal of clinical medicine · 2024Review
- Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations.Rheumatology (Oxford, England) · 2024Review
- Mitral Valve Replacement for Enlarged Libman-Sacks Endocarditis in a Patient with Persistent Primary Antiphospholipid Syndrome and Recurrent Stroke: A Case Report.The American journal of case reports · 2023Article
- Brainstem stroke in a patient with systemic lupus erythematosus and triple antiphospholipid antibody profile.BMJ case reports · 2022Article
- Neuropsychiatric Manifestations of Antiphospholipid Syndrome-A Narrative Review.Brain sciences · 2022Review
- Distinct lesion features and underlying mechanisms in patients with acute multiple infarcts in multiple cerebral territories.Frontiers in neurology · 2022Article
- Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.Current neurology and neuroscience reports · 2021Review
- Multiple embolic strokes in primary antiphospholipid syndrome.European journal of rheumatology · 2020Article
- Ischaemic stroke in young adults: risk factors and long-term consequences.Nature reviews. Neurology · 2014Review
- Ischemic Stroke in the Young.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Ischemic stroke is one of the most common complications of the antiphospholipid syndrome (APS). Because of the relative lack of definitive prospective studies, there is still some debate as to whether the persistent presence of antiphospholipid antibodies (aPLs) increases the risk of recurrent stroke. There is more evidence for aPLs as a risk factor for first stroke. The mechanisms of ischemic stroke are considered to be thrombotic and embolic. APS patients with thrombotic stroke frequently have other, often conventional vascular risk factors. Transesophageal echocardiogram is strongly recommended in APS patients with ischemic stroke because of the high yield of valvular abnormalities. The appropriate management of thrombosis in patients with APS is still controversial because of limited randomized clinical trial data. This review discusses the current evidence for antithrombotic therapy in patients who are aPL positive but do not fulfill criteria for APS, and in APS patients. Alternative and emerging therapies including low molecular weight heparin, new oral anticoagulants (including direct thrombin inhibitors), hydroxychloroquine, statins, and rituximab, are also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.